Chong Kun Dang embarked on the patent challenge of Celebrex

Chong Kun Dang embarked on the patent challenge of Celebrex (Pfizer Korea) which is an absolute leader in the field analgesic and anti-inflammatory.

Celebrex is one of the cox-2 inhibitors for pain relief recording sales of 50 billion won annually, and its patent expires system on June 11 next year. More than 20 domestic pharmaceutical companies have already received approval, and other pharma...